Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MD

Video

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Larry Anderson, MD, PhD, associate professor, Department of Internal Medicine, Division of Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, about the methods utilized in the phase 2 KarMMa trial (NCT03361748) in multiple myeloma (MM).

The KarMMa trial investigated the efficacy and safety of idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory MM. Updated data was presented at the 2021 International Myeloma Workshop.

Prior to ide-cel administration, peripheral blood autologous T cells are taken via leukapheresis from a patient and modified with a viral vector to express a CAR T-cell receptor that recognizes BCMA, a plasma cell–specific surface protein on myeloma cells that is not expressed on other normal tissue, Anderson explains. In the KarMMa trial, 128 patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy were treated with ide-cel across a target dose range of 150 x 106 to 450 x 106 CAR T cells, Anderson adds. Patients had received a median of 6 prior lines of therapy, with a range from 3 to 16, Anderson concludes.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.